
Opinion|Videos|January 27, 2025
Supporting Mothers With Postpartum Depression and Promoting Culturally Sensitive Care
Panelists discuss how faster-acting treatments like zuranolone might improve patient outcomes and quality of life, the initial signs to monitor for assessing effectiveness, barriers to accessing such therapies in underserved populations and strategies to increase accessibility, approaches to ensuring safety while addressing distress in patients with intrusive thoughts, effective strategies for managing sleep issues in postpartum depression (PPD), advice for the psychiatry community when treating PPD, and how to tailor advice for clinicians working with underserved populations.
Advertisement
Episodes in this series

Advertisement
Related to this article

There is a question older than medicine, and perhaps older than philosophy, that psychiatry has largely avoided: What makes us human?

APSARD is preparing US adult ADHD guidelines, delivering long-awaited screening, diagnosis, and treatment recommendations as experts discuss the upcoming release.

Rethink “treatment-resistant depression” by adopting difficult-to-treat depression, verifying adequate trials, and stratifying drivers like trauma and inflammation to improve outcomes.

Once-monthly subcutaneous olanzapine LAI requires no loading doses, oral supplementation, or post-injection monitoring, based on phase 3 SOLARIS data.

Neurosterix advances NTX-253, an oral M4 PAM, into phase 2 for schizophrenia after phase 1 shows promising safety and pharmacokinetics.

Andrew A. Nierenberg, MD, explains how a learning health network helps clinicians measure outcomes and redesign bipolar disorder care together with patients.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The New, Impending Adult ADHD Guidelines
2
Olanzapine LAI (Weltruza) Receives FDA Approval for Schizophrenia
3
Two New MDD Approvals: 5-HT1A Agonism and Adjunctive Atypical Antipsychotics
4
Moving Away From Treatment-Resistant Depression and Toward Difficult-to-Treat Depression
5



